By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Vicus Therapeutics 

55 Madison Avenue
Suite 400
Morristown  New Jersey  07960  U.S.A.
Phone: 973-285-3175 Fax: 973-543-1407


Company News
Vicus Therapeutics Announces Safety And Survival Benefit Of VT-122 In Combination With Anti-Cancer Therapies For Advanced Liver And Pancreatic Cancers 1/16/2015 9:16:00 AM
Vicus Therapeutics Announces Initiation of Phase 2 Trial to Evaluate VT-122 in Patients with Liver Cancer Receiving Nexavar 12/27/2010 9:28:20 AM
Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer 5/1/2008 7:49:38 AM
Vicus Therapeutics' Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels 10/5/2007 9:42:02 AM
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 8/16/2007 9:44:18 AM
Vicus Therapeutics to Present Results from Investigator-led Cancer Cachexia Studies at the 12th Congress of the Japanese Society for Palliative Medicine 6/19/2007 10:51:28 AM
Vicus Therapeutics Announces Participation at 14th International Molecular Medicine Tri-Conference 3/1/2007 9:55:29 AM
John Maki, CEO Of Vicus Therapeutics, Elected To Biotechnology Council Of New Jersey Board Of Trustees 2/6/2007 1:04:55 PM